Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NR3C2
REST API REST API
Homo sapiens
NR3C2 is differentially expressed in 245 experiments: 111 organism parts: amygdala, bone marrow, ... (109 more);, 184 disease states: normal, colon carcinoma, ... (182 more);, 82 cell types 275 cell lines 18 compound treatments and 61 other conditions.
Synonyms MLR, MR
Orthologs MCR_CHICK (Gallus gallus)   Nr3c2 (Mus musculus)   nr3c2 (Danio rerio)   NR3C2 (Bos taurus)   Nr3c2 (Rattus norvegicus)   nr3c2 (Xenopus laevis)   Q3HTT9_CANFA (Canis familiaris)   ENSCAFG00000007813 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, regulation of cell proliferation, hormone binding, transcription, DNA-dependent, metal ion binding, sequence-specific DNA binding, nucleus, protein heterodimerization activity, steroid binding, receptor activity, protein homodimerization activity, steroid hormone receptor activity, zinc ion binding, mineralocorticoid receptor signaling pathway, steroid hormone mediated signaling pathway, excretion, mineralocorticoid receptor activity, cellular sodium ion homeostasis, sequence-specific DNA binding transcription factor activity
InterPro Term Nucl_hrmn_rcpt_lig-bd_core, Znf_hrmn_rcpt
UniProt Accession Q4W5E8, B0ZBF7, B0ZBF6, B0ZBF8, B0ZBF5, P08235, B4E2K8, F5GZH0
Gene-Disease Assocation HYPERTENSION, EARLY-ONSET, AUTOSOMAL DOMINANT, WITH SEVERE EXACERBATION, PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL DOMINANT; PHA1A
Search EB-eye ENSG00000151623
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (34 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
PC3
2
E-GEOD-5258, E-MEXP-2034
U87
2
E-GEOD-20089, E-MEXP-903
U266
1
E-MEXP-1269
Hep3B
1
E-MTAB-37
MCF12A
1
E-MTAB-62
269 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, E-GEOD-13987, ... (43 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-AFMX-5, E-TABM-145, E-GEOD-19069, E-GEOD-6740
macrophage
2
E-GEOD-3982, E-GEOD-5099
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-MEXP-466
activated B-cell
1
E-MEXP-2360
naive B cell
1
E-TABM-702
ovarian cancer
1
E-GEOD-21154
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (55 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-57, E-GEOD-3726, E-MTAB-62
control
3
E-GEOD-16363, E-GEOD-8121, E-GEOD-20295
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
sarcoma
2
E-MTAB-37, E-GEOD-2719
glioblastoma
1
2
E-GEOD-4290, E-MEXP-567, E-MTAB-62
178 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-MEXP-1601, E-GEOD-20719, E-MEXP-1269, ... (13 experiments)

Factor Value U/D Experiments
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
sapphyrin PCI-2053
1
E-GEOD-6400
control
1
E-GEOD-3284
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
trichostatin A
1
E-GEOD-5230
Cxcl12
1
E-GEOD-7307
12 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521
GTE6
1
E-GEOD-21521


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd3
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-1561, E-GEOD-22148, E-GEOD-3013

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-601, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446, E-GEOD-22278, E-MEXP-1273, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-TABM-176, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-548, E-GEOD-3697, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-4883

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Treatment
studied in E-MEXP-973, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Processing time: 0.269 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM